Fabry Disease

A progressive, X-linked lysosomal storage disorder caused by deficient alpha-galactosidase A activity, leading to multi-organ damage affecting the kidneys, heart, and nervous system — frequently undiagnosed for over a decade.

About Fabry Disease

In numbers

Classical prevalence approximately 1 in 40,000–60,000 males globally; estimated 8,000–10,000 patients in the USA.
Newborn screening studies consistently reveal GLA variants 10–30 times more frequently than classical estimates, indicating a large undiagnosed pool of late-onset disease.
An estimated 18,400–27,600 USA Fabry patients remain in an undiagnosed backlog (diagnosed rate: 2.8/100K vs. true prevalence of 8.4–11.2/100K).

Special details

Fabry disease is pan-ethnic; recognised founder effects exist in specific communities including parts of Nova Scotia and West Virginia.
X-linked inheritance means females are commonly affected — variable severity driven by X-inactivation patterns, not merely carrier status.
Cascade family screening after one diagnosis routinely identifies previously unrecognised affected relatives, amplifying the impact of each confirmed case.

Signs and symptoms of Fabry Disease

Mean diagnostic delay is 13.7 years in males and 16.3 years in females — with 64.8% of patients receiving at least one incorrect diagnosis before Fabry disease is identified, typically after irreversible organ damage has accumulated.

Neuropathic pain

Burning or tingling in hands and feet, triggered by exercise, fever, or temperature change, typically from childhood.

Hypohidrosis and heat intolerance

Often dismissed as benign in children and adolescents.

Angiokeratomas

Dark, non-blanching papular skin lesions in a bathing-trunk distribution, appearing from puberty onwards.

Progressive renal damage leading to proteinuria

Chronic kidney disease, and eventually end-stage renal disease without treatment.

Cardiac involvement and premature stroke

The leading causes of death in untreated patients.

Key challenges from product development to launch

Strategy and Business

The wrong disease or indication selected for investment
Indications tackled in the wrong order due to shaky success estimates
R&D returns slipping below the cost of capital

Clinical Development

Trials delayed by low patient recruitment
High screen-failure rates that raise trial cost
Mixed cohorts that make the signals difficult to detect

HEOR, Access & Value

A value case that arrives too late or is underdeveloped
Eligible population under-counted, budget-impact case unsubstantiated
Approved by the regulator, delayed at HTA

Medical Affairs

Fragmented, differently-coded healthcare data
Diagnostic delay that is long and unequal
No shared evidence base across functions

Launch and Commercial

Launch planned without a view of the number of findable patients
Targeting too broad a population slows early uptake
RWE started too late to build the case

How Volv Global Helps

Strategy and Business

Pipeline mistakes compound from the earliest decisions: wrong indication, indications tackled in the wrong order, capital deployed where returns already trail the cost of capital.

inTrigue

Finds the true reachable population per candidate, so indication choices rest on evidence.

volv.global/finding-patients

inFlow

Adds probability-of-success and outcome evidence to help prioritise the pipeline.

volv.global/predict-patient-outcomes

Clinical Development

When patients cannot be found, recruitment stalls and the burn rate climbs. High screen failure rates add to the drain, and a mixed cohort makes the results harder to interpret.

inTrigue

Finds the undiagnosed and mis-coded patients conventional feasibility misses, widening the recruitable pool.

volv.global/finding-patients

inCare

Surfaces diagnosed-but-hidden, trial-eligible patients already in the data, so sites enrol faster.

volv.global/stratifying-patient-cohorts

inFlow

Predicts who will progress or respond, enriching the cohort so the signal is not diluted.

volv.global/predict-patient-outcomes

HEOR, Access & Value

Thin or late evidence lets payers restrict access or cut the price. A poorly sized population exposes the budget case, and HTA demands more than the regulator.

inFlow

Generates the real-world evidence and outcomes payers ask for, ahead of the submission deadline.

volv.global/predict-patient-outcomes

inTrigue

Finds the undiagnosed patients missing from the count, so the eligible population holds up under scrutiny.

volv.global/finding-patients

inCare

Surfaces the diagnosed-but-eligible patients who expand the eligible population count.

volv.global/stratifying-patient-cohorts

Medical Affairs

Fragmented data must be built market by market, slowing decisions. Time to correct diagnosis varies by who the patient is and where they receive care.

inTrigue

Works across fragmented, differently-coded data by design, so insight holds up country to country without a rebuild.

volv.global/finding-patients

inAdvance

Detects patients ahead of typical diagnosis, closing the gap in awareness and pathway that drives unequal delay.

volv.global/earlier-detection

Launch and Commercial

A launch without a view of findable patients is poorly resourced from day one. Targeting too broad a population slows early uptake, and late real-world evidence means the access dossier goes in rushed.